Decreased expression of DARPP-32 in oral premalignant and malignant lesions

Anticancer Research

Volumn 27, Issue 4 B, 2007, Pages 2339-2343

  Pimenta, Flávio Juliano ^a   Horta, Martinho Campolina Rebello ^b   Vidigal, Paula Vieira ^a   De Souza, Bruno Rezende ^a   De Marco, Luiz ^a   Romano Silva, Marco Aurélio ^a   Gomez, Ricardo Santiago ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

DARPP 32; Lip squamous cell carcinoma; Oral leukoplakia; Oral squamous cell carcinoma

Indexed keywords

PHOSPHOPROTEIN DARPP 32;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DYSPLASIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; LOWER LIP; MOUTH CANCER; MOUTH MUCOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS;

EID: 34547794750     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of eighteen major cancers. Int J Cancer 54: 594-606, 1993.
2. Vokes EE, Weichselbaum RR, Lippmans SM and Hong WG: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
3. ARF in patients with severe oral epithelial dysplasia. Cancer Res 62: 5295-5300, 2002.
4. Scully C, Field JK and Tanzawa H: Genetic aberrations in oral or head neck squamous cell carcinoma (SCCHN) 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol 36: 256-263, 2000.
5. Toruner GA, Ulger C, Alkan M, Galante AT, Rinaggio J, Wilk R, Tian B, Soteropoulos P, Hameed MR, Schwalb MN and Dermody JJ: Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genet Cytogenet 154: 27-35, 2004.
6. Bouquot JE, Speight PM and Farthing PM: Epithelial dysplasia of the oral mucosa - Diagnostic problems and prognostic feature. Current Diag Pathol 12: 11-21, 2006.
7. Schepman KP, Der Meiji V, Smeele LE and Van Der Waal I: Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from the Netherlands. Oral Oncol 34: 270-275, 1998.
8. De Visscher JG and Van Der Waal I: Etiology of cancer of the lip: a review. Int J Oral Maxillofac Surg 27: 199-203, 1998.
9. Moore S, Johnson N, Pierce AM and Wilson DF: The epidemiology of lip cancer: a review of global incidence and etiology. Oral Diseases 5: 185-195, 1999.
10. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC Jr, Nairn AC and Greengard P: Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons. Nature 402: 669-671, 1999.
11. Greengard P: The neurobiology of slow synaptic transmission. Science 294: 1024-1030, 2001.
12. Svenningsson P, Nairn AC and Greengard P: DARPP-32 mediates the actions of multiple drugs of abuse. AAPSJ 7: 353-360, 2005.
13. Beckler A, Moskaluk CA, Zaika A, Hampton GM, Powell SM, Frierson HF Jr and El-Rifai W: Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3′,5′-monophosphate-regulated phosphoprotein in common adenocarcinomas. Cancer 98: 1547-1551, 2003.
14. El-Rifai W, Smith MF Jr, Li G, Becker A, Carl VS, Montgomery E, Knuutila S, Moskaluk CA, Frierson HF Jr and Powell SM: Gastric cancer overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Research 62: 4061-4064, 2002.
15. Garcia-Jimenez C, Zaballos MA and Santisteban P: DARPP-32 (dopamine and 3′,5′-cyclic adenosine monophosphate-regulated neuronal phosphoprotein) is essential for the maintenance of thyroid differentiation. Mol Endocrinol 19: 3060-3072, 2005.
16. De Paula AM and Gomez RS: Immunolocalization of p53, glutathione S-tranferase pi and CD57 antigens in oral leukoplakia. Anticancer Res 21: 379-385, 2001.
17. Fienberg AA and Greengard P: The DARPP-32 knockout mouse. Brain Res Rev 31: 313-319, 2000.
18. Belkhiri A, Zaika A, Pidkovka N, Knuutila S, Moskaluk C and El-Rifai W: Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res 65: 6583-6592, 2005.
19. Svennilson J and Aperia A: Dopamine in the developing kidney. Int J Dev Biol 43: 441-443, 1999.
20. Souza BR, Souza RP, Rosa DV, Guimarães MM, Correia H and Romano-Silva MA: Dopaminergic intracellular signal integrating proteins: relevance to schizophrenia. Dialogues Clin Neurosci 8: 95-100, 2006.
21. Basu S and Dasgupta PS: Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Diag Dis Sci 44: 916-921, 1999.
22. Ferone D, Arvigo M, Semino C, Jaquet P, Saveanu A, Taylor JE, Moreau JP, Culler MD, Albertelli M, Minuto F and Barreca A: Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. Am J Physiol Endocrinol Metab 289: 1044-1050, 2005.
23. Ishibashi M, Fujisawa M, Furue H, Maeda Y, Fukayama M and Yamaji T: Inhibition of growth of human small cell lung cancer by bromocriptine. Cancer Res 54: 3442-3446, 1994.
24. Sokoloff P, Riou JF, Martres MP and Schwartz JC: Presence of dopamine D-2 receptors in human tumoral cell lines. Biochem Biophys Res Commun 162: 575-582, 1989.
25. Ebihara Y, Miyamoto M, Fukunaga A, Kato K, Shichinohe T, Kawarada Y, Kurokawa T, Cho Y, Murakami S, Uehara H, Kaneko H, Hashimoto H, Murakami Y, Itoh T, Okushiba S, Kondo S and Katoh H: DARPP-32 expression arises after a phase of dysplasia in an oesophageal squamous cell carcinoma. Brit J Cancer 91: 1-5, 2004.
26. Ostwald C, Gogacz P, Hillmann T, Schweder J, Gundlach K, Kundt G and Barten M: p53 mutational spectra are different between squamous-cell carcinomas of the lip and the oral cavity. Int J Cancer 88: 82-86, 2000.
27. Hansen C, Greengard P, Nairn AC, Andersson T and Vogel WF: Phosphorylation of DARP-32 regulates breast cancer cell migration downstream of the receptor tyrosine kinase DDR1. Experimental Cell Research 312: 4011-4018, 2006.